Near-Infrared Laser Adjuvant for Influenza Vaccine

• Satoshi Kashiwagi ,

  * E-mail: skashiwagi@partners.org (SK); mpoznansky@partners.org (MCP)

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Jianping Yuan,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Benjamin Forbes,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Mathew L. Hibert,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Eugene L. Q. Lee,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Laura Whicher,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Calum Goudie,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Yuan Yang,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Tao Chen,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Beth Edelblute,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Brian Collette,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Laurel Edington,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• James Trussler,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Jean Nezivar,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Pierre Leblanc,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Roderick Bronson,

  Affiliation Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Kosuke Tsukada,

  Affiliation Department of Applied Physics and Physico-Informatics, Faculty of Science and Technology, Keio Universtiy, Kohoku-ku, Yokohama-city, Kanagawa, Japan

  ⨯
• Makoto Suematsu,

  Affiliation Department of Biochemistry, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan

  ⨯
• Jeffrey Dover,

  Affiliation SkinCare Physicians of Chestnut Hill, Chestnut Hill, Massachusetss, United States of America

  ⨯
• Timothy Brauns,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• Jeffrey Gelfand,

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
•  [ ... ],
• Mark C. Poznansky

  * E-mail: skashiwagi@partners.org (SK); mpoznansky@partners.org (MCP)

  Affiliation Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

  ⨯
• [ view all ]
• [ view less ]